Mixed clinical results led shares of Arvinas Inc. (NASDAQ:ARVN) to close March 11 at $8.30, down $9.26, or 52%, after the ...
Pfizer is calling for the FDA to issue guidance on what originator companies can say about cheaper biosimilars of their products, and prevent them using “scare tactics” to keep doctors ...
Drugs in late-stage development may mean competition on price for two Pfizer medications that, by some accounts, are the most expensive cardiac medications in history. Transthyretin amyloid ...
As U.S. regulatory uncertainty swirls around the vaccine space and health care in general, Vaxcyte Inc. stands poised for a readout of phase II infant data by the end of this quarter with VAX-24, the ...
INCHEON, Corea del Sur--(BUSINESS WIRE)--Celltrion ha anunciado hoy que la Comisión Europea (CE) ha concedido la autorización de comercialización para Avtozma ® (CT-P47), un biosimilar con ...
Panelists discuss how stakeholders can enhance biosimilar uptake through coordinated efforts in financial alignment, patient-centric pricing, professional education, simplified administrative ...
Pfizer has formed a clinical trial collaboration ... settlement Just as Samsung Bioepis’ partner Sandoz launched a biosimilar to Johnson & Johnson’s Stelara, the Korean company is facing ...
The FDA has approved 5 bevacizumab biosimilars that reference Avastin (bevacizumab). Amgen’s Mvasi (bevacizumab-awwb) received approval in September 2017, followed by the approval of Zirabev ...
Conservative commentator Megyn Kelly claimed the Pfizer COVID vaccine left her with an auto-immune disorder in explosive new comments on her latest podcast episode Wednesday. Kelly, 54 ...
Merilog is a rapid-acting human insulin analog and the first rapid-acting insulin biosimilar product approved by the Food and Drug Administration. HealthDay News — The U.S. Food and Drug ...
A London hospital is to investigate why over half of its patients with multiple sclerosis (MS) who switched from disease modifying therapy Tysabri (natalizumab) to biosimilar Tyruko have had to be ...
Johnson & Johnson is suing Samsung Bioepis for allegedly breaching the terms of a contract regarding the launch of the Korean biotech’s Stelara biosimilar. … ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback